Welcome to our dedicated page for Ovid Therapeutics SEC filings (Ticker: OVID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ovid Therapeutics Inc. filings document a Nasdaq-listed biopharmaceutical company focused on small-molecule medicines for CNS disorders involving neuronal hyperexcitability. Its regulatory record includes 8-K disclosures for clinical program updates, operating and financial results, leadership and compensation arrangements, Nasdaq compliance, and capital-structure events involving common stock, preferred stock, warrants and pre-funded warrants.
Proxy statements disclose board and executive governance, equity compensation, shareholder meeting proposals, authorized-share matters, and stockholder votes required under Nasdaq rules for securities issuances. The filings also record material agreements, risk and governance subjects, and exhibits related to the company’s OV350, OV4071 and OV329 development programs.
Fitzgerald Kevin Joseph reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. director Kevin Joseph Fitzgerald reported receiving an employee stock option grant covering 65,000 shares of common stock. The option was awarded on February 26, 2026 and is scheduled to vest in full on February 26, 2027, provided he remains in continuous service through that date.
Friedman Bart reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. director Bart Friedman reported receiving an equity award in the form of an employee stock option covering 65,000 shares. The option was granted at no cost on February 26, 2026 and will vest in full on February 26, 2027, provided he remains in continuous service through that date.
DUNCAN BARBARA GAYLE reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Barbara Gayle Duncan received a grant of employee stock options covering 65,000 shares on February 26, 2026. The options have a stated price of $0.0000 per share and will vest in full on February 26, 2027, subject to her continuous service through that vesting date.
Bernstein Karen reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Karen Bernstein was granted employee stock options covering 65,000 shares of Ovid common stock. The award was made on February 26, 2026 and is reported at a grant price of $0.00 per share in this filing.
According to the terms, the option will vest in full on February 26, 2027, as long as Bernstein continues to provide service to the company through that date. After vesting, the option will become exercisable for the underlying shares, subject to the company’s equity plan and any applicable restrictions.
Ovid Therapeutics Inc. chief business and financial officer Rona Jeffrey reported a mix of equity grants and a small tax-related sale. On February 26, 2026, Jeffrey received an option to purchase 408,750 shares of Common Stock and a grant of 68,125 shares of Common Stock as a restricted stock unit award, both at a price per share of $0.00. The RSUs vest in three equal annual installments beginning February 20, 2027, and the stock options vest in 48 equal monthly installments beginning March 20, 2026, conditioned on continued service.
On February 23, 2026, Jeffrey sold 8,541 shares of Common Stock at a weighted average price of $1.45 per share. According to the disclosure, this sale was a mandatory “sell to cover” transaction to satisfy statutory tax withholding obligations triggered by restricted stock unit vesting, not a discretionary sale decision.
Ovid Therapeutics Inc. Schedule 13G discloses that ADAR1-related parties report beneficial ownership of 9,284,166 shares of Common Stock, equal to 6.9% of the class. The filing attributes these holdings to ADAR1 Capital Management, ADAR1 Capital Management GP and Daniel Schneeberger and ties the percentage to December 15, 2025, based on 130,184,353 shares outstanding reported in the issuer's prospectus.
Ovid Therapeutics Inc. received an updated ownership report from Affinity Asset Advisors, LLC and Michael Cho. The reporting persons beneficially own 12,149,166 shares of Ovid common stock, including 4,999,166 shares issuable upon exercise of warrants, representing approximately 9.0% of the outstanding common stock.
The securities are held through Affinity Healthcare Fund, LP, over which Affinity Asset Advisors acts as investment manager and Michael Cho is the managing member. The filers state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Ovid.
Federated Hermes, Inc. and related parties have filed a Schedule 13G reporting beneficial ownership of 7,737,166 shares of Ovid Therapeutics Inc. common stock, representing 5.94% of the class as of the 12/31/2025 event date. Federated Hermes and the Voting Shares Irrevocable Trust report sole voting and dispositive power over these shares, while individuals Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue report shared voting and dispositive power over the same 7,737,166 shares.
The reporting persons state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Ovid Therapeutics. Federated Hermes, the trust, and the individual filers expressly disclaim beneficial ownership of securities held by the managed funds referenced in the filing.
Ovid Therapeutics Inc.'s CEO and director reported a set of insider transactions involving preferred stock, warrants, and common shares. On December 11, 2025, the reporting person purchased 71 investment units at $1,400 per unit, each unit consisting of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock.
Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares of common stock at 5 p.m. Eastern Time on December 15, 2025, resulting in 71,000 common shares after stockholder approval on December 11, 2025. Following these transactions, the reporting person directly beneficially owned 3,687,715 common shares and indirectly held 35,461 common shares through Divo Holdings, LLC, while disclaiming beneficial ownership of those indirect shares.